Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2276 - 2300 of 14935 in total
Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
Approved
Matched Description: … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for …
A beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias.
Approved
Approved
Nutraceutical
Matched Categories: … Amino Acids, Peptides, and Proteins …
Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … triglyceride levels and liver and kidney dysfunction. ... [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines ... nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384,...
Approved
Investigational
Matched Description: … treatment for HGPS and other related progeroid laminopathies. ... [A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed ... [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Investigational
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express...
Approved
Matched Description: … It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular ... kill cancer cells, and are infused back into the patient. ... collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Sotatercept is an activin signalling inhibitor. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension...
Approved
Investigational
Matched Description: … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration.[L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim...
Approved
Matched Description: … GC-627-05 in the US and Europe respectively. ... thus reducing the severity and duration of neutropenia. ... A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over 77 years [A174778,...
Approved
Matched Description: … kidney tissue damage, and anaphylactic reaction, amongst others [A174778, L5371]. ... reversal predominantly via the formation of an inactive complex between the anionic nature of heparin and ... potential range in reversing all parenteral anticoagulants are sometimes considered high and limited …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is...
Approved
Investigational
Matched Description: … [A218186, L32118] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. ... lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is...
Approved
Vet approved
Matched Description: … (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) ... It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures ... anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and
Matched Categories: … Antiglaucoma Preparations and Miotics ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Approved
Investigational
Withdrawn
Matched Description: … CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy...
Approved
Investigational
Matched Description: … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and ... approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …
Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the...
Approved
Investigational
Matched Description: … in providing protection against infection and irritating agents. ... It stimulates synthesis and release of surfactant by type II pneumocytes. ... The substance is a mucoactive drug with several properties including secretolytic and secretomotoric …
Matched Categories: … Cough and Cold Preparations ... clenbuterol and ambroxol …
Thiram may be used in dermatology as a scabicide . Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for safety in many markets including Canada .
Approved
Experimental
Matched Description: … Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated …
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Approved
Vet approved
Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer...
Approved
Investigational
Matched Description: … Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. ... [L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults. ... [A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such...
Approved
Investigational
Matched Description: … hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair...
Approved
Investigational
Matched Description: … and ovarian cancer. ... and DNA repair machinery. ... Both the European Commission and the U.S. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes. It was developed by MCPRF and FDA first approved in September 2012.
Approved
Investigational
Matched Description: … [A32041] It was developed by MCPRF and FDA first approved in September 2012. …
Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression...
Approved
Investigational
Matched Description: … It produces consistent but acceptable myelosuppression and cardiotoxic effects. ... It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in …
Matched Categories: … Indicators and Reagents ... Antineoplastic and Immunomodulating Agents …
Displaying drugs 2276 - 2300 of 14935 in total